Who
Robert E. Hoffman
Director
Company insider
Files Form 4 as: Director, Esperion Therapeutics; Director, FibroBiologics; Chief Financial Officer, CytoDyn; President, CEO and Interim CFO, TuHURA Biosciences; Director, Kura Oncology; CFO & SVP, Finance, Heron Therapeutics; Director, Aravive; Director, CombiMatrix.
In numbers
- Trades disclosed
- 119
- Buys
- 3
- Sells
- 6
- Bought
- $66K
- Sold
- $2.4M
- Companies
- 11
- Companies where not an officer
- 6
- First trade
- 30 Dec 2005
- Last trade
- 13 Jul 2026
- Last filed
- 13 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Jul 2026filed 13 Jul 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Code D | —85,153 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,040 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code D | —7,040 | filing |
| 13 Jul 2026filed 13 Jul 2026 | Esperion Therapeutics | SEC FORM 4 Code D | —85,153 | filing |
| 23 Jun 2026filed 23 Jun 2026 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,803 at $0.00 | filing |
| 23 Jun 2026filed 23 Jun 2026 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,803 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | Esperion TherapeuticsBiotechnology | SEC FORM 4 Code A | —79,873 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | Esperion Therapeutics | SEC FORM 4 Code A | —79,873 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CytoDynoption or derivative | SEC FORM 4 Code A | —4,874,691 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | HURA TuHURA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —156,240 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | HURA TuHURA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —156,240 at $0.00 | filing |
| 12 Jun 2025filed 12 Jun 2025 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —7,040 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | Esperion Therapeutics | SEC FORM 4 Code A | —5,280 at $0.00 | filing |
| 15 May 2025filed 22 May 2025 | CytoDynoption or derivative | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | HURA TuHURA Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,275 at $0.00 | filing |
| 27 Aug 2024filed 27 Aug 2024 | FBLG FibroBiologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
News
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officermanilatimes.net · 19 Oct 2026TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025HURA · prnewswire.com · 13 Oct 2026
1 headline in the last 90 days name Robert E. Hoffman; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.